The Medical Research Agency funds research at Białystok Medical University and Stefan Cardinal Wiesinski’s National Heart Institute. They need to check the effectiveness of “levosimendan” and determine the optimal drug therapy and the time for administration of anticoagulants to patients.
On the occasion of the upcoming World Heart Day, which was established on the initiative of the World Heart Federation, the Medical Research Agency reminds of the growing problem of heart failure.
“The annual mortality rate due to exacerbation of the disease is 15%. Half of patients die within five years. The rate of readmission to hospital due to heart failure is 25% annually. Heart failure is currently the largest epidemic and curative problem in heart disease” – the Medical Research Agency reported.
According to the professor. Agnieszka Tycińska of the Department of Cardiology at Białystok Medical University, drugs that have been used so far to stimulate the heart to contract put patients at risk.
“Medications that stimulate the heart to contract, used to exacerbate heart failure, increase the oxygen debt of heart cells, which translates into a worse prognosis for patients. Therefore, at the moment we do not have an effective and safe treatment for patients with heart failure. Severe heart failure, “- she said.
She noted that the breakthrough in this case may be the regular use of levosimendan. It does not have a harmful effect like other preparations.
She noted, “The main advantage of levosimendan, which distinguishes it from other drugs that stimulate the heart to contract, is to reduce the heart’s energy consumption in terms of the efficiency of contraction. Therefore, this drug does not increase the oxygen demand of the heart muscle.”
In order to verify the efficacy of levosimendan, the Bialystok Medical University will conduct the LEIA-HF (Levosimendan in Patients with Ambulatory Heart Failure) study to determine the efficacy of repeated injections of levosimendan in outpatients with advanced systolic heart failure. 350 patients with severe heart failure will participate.
“With the positive results, the short-term health impact that Bialystok Medical University expects, compared to the current standard of treatment, is to save 3,750 people in Poland from death or exacerbation of acute heart failure and stay in hospital within a year. Life expectancy after heart failure diagnosis And it will improve its quality. At the same time, it will allow many patients to survive until a heart transplant or a circulatory support transplant “- reported ABM.
The aging of the Polish community leads to an increase in the number of cardiac intravascular structural procedures being performed. In some cases, they are invasive and require atrial septal perforation or leave an artificial material in the cavities of the left heart.
The British Pharmaceutical Industry Association wrote: “This poses a risk of iatrogenic clot formation and, consequently, embolic stroke or systemic embolism. To avoid it, patients undergo drug therapy to reduce blood clotting, which increases the risk of major bleeding.”
For this purpose, the Stefan Cardinal Wiesinski National Institute of Cardiology will conduct a study “Optimal pharmacotherapy in structural procedures with interatrial septal access in the periphery of wounds (STOP CLOT Trial) and in the medium term (SAFE LAAC Trial)”.
“The project will include patients undergoing procedures with an atrial septal approach. These are patients with mitral valve regurgitation treated with tip-to-edge + (TEER) technology using the MitraClip or PASCAL system, and patients with atrial fibrillation undergoing closure of the left atrial appendix Surgery (LAAC) ”- the Medical Research Agency reported.
A second study will also be conducted. “In a study + strategy for improving intraoperative anticoagulation in septal + structural surgery, the scientists want to determine the optimal time to start intraoperative heparin anticoagulation,” she added.
According to the professor. Dr. Jerzy Pręgowski of the Anin Cardiology Institute, the earlier anticoagulant treatment is started, the lower the risk of embolism.
“Early initiation of peripheral anticoagulant therapy in patients undergoing percutaneous mitral regurgitation and left atrial appendage closure will reduce the risk of embolizing complications, including strokes and ischemic events in the brain” – emphasized.
“Study participants have three times (once before the procedure and twice after the procedure) an MRI of the brain to detect possible new ischemic changes. In addition, they have three psychological tests to assess cognitive abilities and blood is taken to assess the concentration of brain markers of ischemia “- added (PAP) )
Author: Wojciech Wierzbicki
wet / nut /
“Internet Geek. Food Enthusiast. Thinker. Beer Practitioner. Bacon Specialist. Music Addict. Traveler.”